Publication & Citation Trends
Publications
0 total
2784P Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemo-immunotherapy (CT-IO): An international multicentric analysis
Cited by 0
Semantic Scholar
P3.13.04 Consolidation Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC: A Multicentric Retrospective Analysis
Cited by 0
Semantic Scholar
LBA101 Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase III DeLLphi-304 trial
Cited by 0
Semantic Scholar
1992P Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer
Cited by 0
Semantic Scholar
CO169 Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Cited by 0
Semantic Scholar
LBA100 Detailed safety analysis of DeLLphi-304: The first phase III study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Cited by 2
Semantic Scholar
2773P Patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients (Pts) with previously treated small cell lung cancer (SCLC)
Cited by 0
Semantic Scholar
312P: Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemoimmunotherapy (CT-IO)
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(268)
Lung Cancer Research Studies
(237)
Cancer Genomics and Diagnostics
(114)
Lung Cancer Diagnosis and Treatment
(113)
Neuroendocrine Tumor Research Advances
(89)
Affiliations
AstraZeneca (United Kingdom)
Ontario Institute for Cancer Research
Hebron University
National Health Service
University Health Network